This year GSK acquired Bellus Health for US$2 billion. Bellus Health had 1 drug, Camlipixant which is currently in phase 3; cash, cash equivalents and short-term investments totalling US$313 million. Jefferies analysts estimated camlipixant could generate peak U.S. sales of $1.2 billion. GSK’s chief commercial officer, told a media briefing “We expect to continue doing deals like this."
Wouldnt it be nice, page-20
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
-0.005(1.47%) |
Mkt cap ! $608.8M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 34.3¢ | 32.5¢ | $1.200M | 3.588M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 349093 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 25403 | 5 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |